Eliza Gordon-Lipkin, M.D.
Metabolic Medicine Branch
M.D. University of Maryland, Baltimore
Biography
Dr. Gordon-Lipkin is a researcher and child neurologist with expertise in neurodevelopmental disabilities in the Metabolism, Infection and Immunity (MINI) Section, at NHGRI. She completed her medical training from the University of Maryland in Baltimore; residency in pediatrics from the Mount Sinai Kravis Children’s Hospital in New York City; fellowship and subspeciality training in Child Neurology and Neurodevelopmental Disabilities from the Johns Hopkins School of Medicine and Kennedy Krieger Institute, respectively, where she acquired expertise in neurogenetic and neuroimmune disorders. In 2018, she joined the MINI Section at NHGRI as a staff clinician and assistant research physician. Dr. Gordon-Lipkin currently sees patients with neurodevelopmental disabilities specifically focusing on mitochondrial, neuroinfectious and neuroinflammatory disorders in children.
Scientific Summary
Dr. Gordon-Lipkin’s longstanding research interests focus on the effects of infection and inflammation on brain development and harnessing this knowledge to optimize clinical care for children with neurodevelopmental disabilities. Her prior work spans multiple neuroinflammatory conditions including autoimmune encephalitis, acute flaccid myelitis, and multiple sclerosis. Her current work with Dr. Peter McGuire in the MINI Section at NHGRI focuses on immune phenotyping of mitochondrial disease to better understand why infections lead to neurologic decline in these patients. She is the principal investigator of two clinical research protocols for mitochondrial disease at the NIH Clinical Center. Her recent publications have identified deficits in humoral immunity in this patient population.
Publications
Gordon-Lipkin EM, Banerjee P, Thompson E, Kruk S, Franco JLM, McGuire PJ. Epitope-level profiling in children with mitochondrial disease reveals limitations in the antibacterial antibody repertoire. Mol Genet Metab. 2023 Jun;139(2):107581.
Warren E, Gordon-Lipkin EM, Cheung F, Chen J, Mukherjee A, Apps R, et al. Inflammatory and interferon gene expression signatures in patients with mitochondrial disease. Res Sq. 2023 Feb 27; rs.3.rs-2612547.
Gordon-Lipkin EM, Marcum CS, Kruk S, Thompson E, Kelly SEM, Kalish H, et al. Comprehensive profiling of the human viral exposome in households containing an at-risk child with mitochondrial disease during the 2020-2021 COVID-19 pandemic. Clin Transl Med. 2022 Nov;12(11):e1100.
Yeshokumar A, Gordon-Lipkin E, Arenivas A, Rosenfeld M, Patterson K, Blum R, et al. Younger Age at Onset Is Associated With Worse Long-term Behavioral Outcomes in Anti-NMDA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022 Jul 6;9(5): e200013.
Gordon-Lipkin EM, Marcum C, Kruk S, Thompson E, Kelly SEM, Kalish H, et al. Undiagnosed COVID-19 in households with a child with mitochondrial disease. medRxiv. 2022 Mar 23; 2022.03.21.22272358.
Gordon-Lipkin E, Kruk S, Thompson E, Yeske P, Martin L, Hirano M, et al. Risk mitigation behaviors to prevent infection in the mitochondrial disease community during the COVID-19 pandemic. Mol Genet Metab Rep. 2022 Mar;30:100837.
Sturrock BRH, Macnamara EF, McGuire P, Kruk S, Yang I, Murphy J, Tifft CJ, Gordon-Lipkin E. Progressive cerebellar atrophy in a patient with complex II and III deficiency and a novel deleterious variant in SDHA: A counseling conundrum. Mol Genet Genomic Med. 2021 Jun;9(6):e1692.
Gordon-Lipkin E, Hoon A, Pardo CA. Prenatal cytomegalovirus, rubella, and Zika virus infections associated with developmental disabilities: past, present, and future. Dev Med Child Neurol. 2021 Feb;63(2):135-143.
Kruk SK, Pacheco SE, Koenig MK, Bergerson JRE, Gordon-Lipkin E, McGuire PJ. Vulnerability of pediatric patients with mitochondrial disease to vaccine-preventable diseases. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2415-2418.e3.
Gordon-Lipkin E, Peacock G. The spectrum of developmental disability with Zika exposure: What is known, what is unknown, and implications for clinicians. J Dev Behav Pediatr. 2019 Jun;40(5):387-395.
Gordon-Lipkin E, Muñoz LS, Klein JL, Dean J, Izbudak I, Pardo CA. Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease. Dev Med Child Neurol. 2019 Mar;61(3):366-375.
Rothman A, Murphy OC, Fitzgerald KC, Button J, Gordon-Lipkin E, Ratchford JN, et al. Retinal measurements predict 10-year disability in multiple sclerosis. Ann Clin Transl Neurol. 2019 Feb;6(2):222-232.
Elrick MJ, Gordon-Lipkin E, Crawford TO, Van Haren K, Messacar K, Thornton N, et al. Clinical subpopulations in a sample of North American children diagnosed with acute flaccid myelitis, 2012-2016. JAMA Pediatr. 2019 Feb 1;173(2):134-139.
Gordon-Lipkin E, Cohen JS, Srivastava S, Soares BP, Levey E, Fatemi A. ST3GAL5-related disorders: A deficiency in ganglioside metabolism and a genetic cause of intellectual disability and choreoathetosis. J Child Neurol. 2018 Nov;33(13):825-831.
Gordon-Lipkin E, Fatemi A. Current therapeutic approaches in leukodystrophies: A Review. J Child Neurol. 2018 Nov;33(13):861-868.
Gordon-Lipkin E, Marvin AR, Law JK, Lipkin PH. Anxiety and mood disorder in children with autism spectrum disorder and ADHD. Pediatrics. 2018 Apr;141(4).
Yeshokumar AK, Gordon-Lipkin E, Arenivas A, Cohen J, Venkatesan A, Saylor D, et al. Neurobehavioral outcomes in autoimmune encephalitis. J Neuroimmunol. 2017 Nov 15;312:8-14.
Gordon-Lipkin E, Yeshokumar AK, Saylor D, Arenivas A, Probasco JC. Comparative outcomes in children and adults with anti- N-methyl-D-aspartate (anti-NMDA) receptor encephalitis. J Child Neurol. 2017 Oct;32(11):930-935.
Gordon-Lipkin E, Gentner MB, German R, Leppert ML. Neurodevelopmental outcomes in 22 children with microcephaly of different etiologies. J Child Neurol. 2017 Aug;32(9):804-809.
Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007 Oct 16;69(16):1603-9.
Last updated: November 6, 2023